SCHEMBL5646247

SCHEMBL5646247

O=C(CC1Nc2ccccc2NC1=O)Nc1ccc(O)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.82
ALDH1A1 P00352 9/20 0.82
MEN1 O00255 9/20 0.82
KMT2A Q03164 9/20 0.82
KDM4E B2RXH2 7/20 0.82
RAB9A P51151 1/20 0.82
HSD17B10 Q99714 1/20 0.82
TP53 P04637 2/20 0.74
MST1R Q04912 1/20 0.74
GAA P10253 12/20 0.71
POLB P06746 2/20 0.70
NTSR1 P30989 1/20 0.70
HTT P42858 1/20 0.70
SMN1; SMN2 Q16637 2/20 0.69
LMNA P02545 3/20 0.66
HPGD P15428 3/20 0.66
CASP1 P29466 2/20 0.66
L3MBTL1 Q9Y468 1/20 0.65
BLM P54132 1/20 0.65
PLEC Q15149 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13166883 0.85 MST1R (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5646856 0.77 TP53 (0.69) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL22144484 0.76 GAA (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL10077846 0.76 MAPT (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL10077845 0.76 GAA (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4420851 0.75 ALDH1A1 (0.74) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4425365 0.75 ALDH1A1 (0.74) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6698946 0.75 MAPT (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6701145 0.75 KDM4E (0.77) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4418592 0.75 KDM4E (0.77) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL MAPT 4693/4885ALDH1A1 1304/4885MEN1 2277/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL MAPT 4668/4885ALDH1A1 1599/4885MEN1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.